pre_eclampsia logo

Disorders of pregnancy touch all parts of our world, access to rapid decision making tools can literally save the lives of both mothers and babies. Our first product for the management of pregnancy is the CercaTest™ Pre-eclampsia Vue™ assay. Using the well-established correlation between the excretion of misfolded proteins and the core causes of pre-eclampsia, we have developed a simple cost effective test that can be used in hospitals, in primary care and hopefully in time by patients themselves to check that signs and symptoms of pre-eclampsia do not become life threatening.

In 2014, Professor Irina Buhimschi then at Yale University first published her discovery of the presence of misfolded proteins in urine samples from pregnant women and their correlation with pre-eclampsia.

Congophilia (binding affinity of misfolded proteins to Congo red dye), a long-known property of misfolded proteins, was employed to detect misfolded proteins in urine samples from pregnant women. Diagnosis of pre-eclampsia based on Congophilia was later validated independently by researchers in the US, the UK, Israel, India, Mexico, and China.

Several methods and devices have been developed to detect Congophilia and diagnose pre-eclampsia. Our CercaTest™ Pre-eclampsia VueTM, is an innovative device based on a novel technique that enables a simple and accurate point-of-care test of pre-eclampsia within 5 minutes.

Pre-Eclampsia Vue™

Clinical utility and validation

CercaTest™ Pre-Eclampsia Vue™ is a new version of a well documented technique to detect misfolded proteins in the urine of pregnant mothers. In multiple studies this is shown to be an indicator of poor pregnancy outcomes.

READ MORE +

Pre-Eclampsia Vue™

Method

CercaTest™ Pre-Eclampsia Vue™ uses a 2 stage process for detecting misfolded proteins, first the sample is mixed in a pipette with the Congo Red dye, unbound dye is then internally filtered out and only bound dye flows into the reaction cuvette.

READ MORE +